PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.68%
Negative EBIT growth while Biotechnology median is -1.25%. Seth Klarman would check if external or internal factors caused the decline.
-2.68%
Negative operating income growth while Biotechnology median is -2.18%. Seth Klarman would check if structural or cyclical issues are at play.
-2.79%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
1.20%
EPS growth of 1.20% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
2.99%
Diluted EPS growth of 2.99% while Biotechnology median is zero. Walter Schloss might see a slight edge that could improve over time.
3.80%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.10%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
35.18%
OCF growth of 35.18% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
35.60%
FCF growth of 35.60% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13691.29%
Negative 10Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
29.84%
OCF/share CAGR of 29.84% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
58.26%
3Y OCF/share growth of 58.26% while Biotechnology median is zero. Walter Schloss might see a modest advantage that could compound if momentum holds.
-7976.92%
Negative 10Y net income/share CAGR vs. Biotechnology median of 0.00%. Seth Klarman might see a fundamental problem if peers maintain growth.
76.35%
Net income/share CAGR of 76.35% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
62.71%
3Y net income/share CAGR of 62.71% while Biotechnology median is zero. Walter Schloss might see a small advantage that can be scaled further.
1259.19%
Equity/share CAGR of 1259.19% while Biotechnology median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
224.33%
5Y equity/share CAGR of 224.33% while Biotechnology median is zero. Walter Schloss sees a slight positive that might compound if management executes well.
-84.52%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.18%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-26.68%
Negative BV/share change while Biotechnology median is -0.01%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
No Data
No Data available this quarter, please select a different quarter.
20.47%
R&D growth of 20.47% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
-32.93%
SG&A decline while Biotechnology grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.